Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$30.16 USD
-0.06 (-0.20%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $30.35 +0.19 (0.63%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KYMR 30.16 -0.06(-0.20%)
Will KYMR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for KYMR
Kymera Therapeutics Shareholders Approve Key Governance Proposals
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Buy Rating Affirmed for Kymera Therapeutics’ KT-333 on Strong Clinical Data and Therapeutic Potential
Wall Street Analysts Are Bullish on Top Healthcare Picks
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting